TI
KERX

Trexquant Investment’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Trexquant Investment’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-17,353
Closed -$115K – 1143
2016
Q2 		$115K Buy
+17,353
New +$97K 0.02% 818

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Trexquant Investment's KERX Position: Q3 2016 in Review

Trexquant Investment sold out of Keryx Biopharmaceuticals Inc (KERX) in Q3 2016, closing a stake of 17,353 shares — an estimated $115K sold.

Trexquant Investment first reported a position in KERX in Q2 2016 and held it in 1 quarter. The position peaked at $115K in Q2 2016. 116 funds tracked by Wall St. Rank hold KERX as of Q3 2016.

  • Trexquant Investment reported no remaining Keryx Biopharmaceuticals Inc position as of Q3 2016 after selling out during the quarter.
  • Trexquant Investment sold 17,353 Keryx Biopharmaceuticals Inc shares in Q3 2016, an estimated $115K.
  • Trexquant Investment first reported a position in Keryx Biopharmaceuticals Inc in Q2 2016 and held it in 1 quarter.
  • Trexquant Investment's Keryx Biopharmaceuticals Inc position peaked at $115K in Q2 2016.
  • 116 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q3 2016.

Based on Trexquant Investment's 13F filing for Q3 2016, filed 10 Nov 2016.